12:00 AM
Jun 08, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral salmon calcitonin: Complete Phase III enrollment

Novartis and Nordic completed enrollment of more than 900 patients ages 51-80 in a 2-year, double-blind, placebo-controlled, international Phase III trial evaluating 0.8 mg of oral SMC021 given twice daily. In 2000, Emisphere granted exclusive rights for SMC021 to...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >